Consistent with the idea that HRG is a brain growth factor exploited by metastatic cells, HER3 is induced and activated in brain metastases compared to matching breast and lung cancers [23, 24] and patients with HER2-positive breast cancer are at high risk of brain relapse [4, 6]. This evidence concerns the gene ERBB3 and lung carcinoma.